

# **Guidelines for the treatment of malaria**



**World Health  
Organization**

## WHO Library Cataloguing-in-Publication Data

Guidelines for the treatment of malaria/World Health Organization.

Running title: WHO guidelines for the treatment of malaria.

1. Malaria – drug therapy. 2. Malaria – diagnosis. 3. Antimalarials – administration and dosage. 4. Drug therapy, Combination. 5. Guidelines. I. Title. II. Title: WHO guidelines for the treatment of malaria.

ISBN 92 4 154694 8

(NLM classification: WC 770)

ISBN 978 92 4 154694 2

WHO/HTM/MAL/2006.1108

© World Health Organization, 2006

All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. The named authors alone are responsible for the views expressed in this publication.

For more information, please contact:

Dr P. Olumese

Global Malaria Programme

World Health Organization

20, avenue Appia – CH-1211 Geneva 27

Tel. +41 22 791 4424

Fax +41 22 791 4824

E-mail: [olumesep@who.int](mailto:olumesep@who.int)

Printed in Switzerland

Design: B. Duret – Cover: T. Cailler

---



---



---

1.1	Background	1
1.2	Objectives and target audience	2
1.3	Methods used in developing the guidelines and recommendations	3

---

3.1	Uncomplicated malaria	7
3.2	Severe malaria	7

---

4.1	Clinical diagnosis	8
4.2	Parasitological diagnosis	9
4.3	Where malaria transmission is low–moderate and/or unstable	10
4.4	In stable high-transmission settings	10
4.5	Malaria parasite species identification	11
4.6	In epidemics and complex emergencies	11

---

5.1	Impact of resistance	12
5.2	Global distribution of resistance	12
5.3	Assessing resistance	13

---

6.1	Assessment of <i>in vivo</i> therapeutic efficacy	14
6.2	Criteria for antimalarial treatment policy change	15

---

***P. falciparum***

7.1	Assessment	16
7.2	Antimalarial combination therapy	16
7.3	The choice of artemisinin based combination therapy options	20
7.4	Practical aspects of treatment with recommended ACTs	23
7.5	Incorrect approaches to treatment	26
7.6	Additional aspects of clinical management	27
7.7	Operational issues in treatment management	29
7.8	Management of treatment failures	31
7.9	Treatment in specific populations and situations	32
7.10	Coexisting morbidities	38

---

---

8.1	Definition	41
8.2	Treatment objectives	41
8.3	Clinical assessment	42
8.4	Specific antimalarial treatment	42
8.5	Practical aspects of treatment	47
8.6	Follow-on treatment	48
8.7	Pre-referral treatment options	49
8.8	Adjunctive treatment	51
8.9	Continuing supportive care	53
8.10	Additional aspects of clinical management	54
8.11	Treatment during pregnancy	58
8.12	Management in epidemic situations	59
8.13	Hyperparasitaemia	60

---

	<i>P. vivax</i> <i>P. ovale</i> <i>P. malariae</i>	
9.1	Diagnosis	62
9.2	Susceptibility of <i>P. vivax</i> , <i>P. ovale</i> and <i>P. malariae</i> to antimalarials	63
9.3	Treatment of uncomplicated vivax malaria	63
9.4	Treatment of severe vivax malaria	66
9.5	Treatment of malaria caused by <i>P. ovale</i> and <i>P. malariae</i>	66
9.6	Monitoring therapeutic efficacy for vivax malaria	66

---

11.1	Diagnosis	69
11.2	Use of rapid diagnostic tests in epidemic situations	69
11.3	Management of uncomplicated malaria in epidemics	70
11.4	Areas prone to mixed falciparum/vivax malaria epidemics	70
11.5	Use of gametocytocidal drugs to reduce transmission	71
11.6	Anti-relapse therapy in vivax malaria epidemics	71
11.7	Mass treatment	71

---

Annex 1.	The guidelines development process	77
Annex 2.	Adaptation of WHO malaria treatment guidelines for use in countries	83
Annex 3.	Pharmacology of antimalarial drugs	87
Annex 4.	Antimalarials and malaria transmission	133
Annex 5.	Malaria diagnosis	147
Annex 6.	Resistance to antimalarials	155
Annex 7.	Uncomplicated <i>P. falciparum</i> malaria	185
Annex 8.	Malaria treatment and HIV/AIDS	198
Annex 9.	Treatment of severe <i>P. falciparum</i> malaria	207
Annex 10.	Treatment of <i>P. vivax</i> , <i>P. ovale</i> and <i>P. malariae</i> infections	225
	Index	240

## GLOSSARY

A combination of artemisinin or one of its derivatives with an antimalarial or antimalarials of a different class.

The life-cycle of the malaria parasite in host red blood cells (intra-erythrocytic development) from merozoite invasion to schizont rupture (merozoite → ring stage → trophozoite → schizont → merozoites). Duration approximately 48 h in *Plasmodium falciparum*, *P. ovale* and *P. vivax*; 72 h in *P. malariae*.

The presence in host red blood cells of asexual parasites. The level of asexual parasitaemia can be expressed in several different ways: the percentage of infected red blood cells, the number of infected cells per unit volume of blood, the number of parasites seen in one microscopic field in a high-power examination of a thick blood film, or the number of parasites seen per 200–1000 white blood cells in a high-power examination of a thick blood film.

Severe falciparum malaria with coma (Glasgow coma scale <11, Blantyre coma scale <3). Malaria with coma persisting for >30 min after a seizure is considered to be cerebral malaria.

A combination of two or more different classes of antimalarial medicines with unrelated mechanisms of action.

Elimination of the symptoms and asexual blood stages of the malaria parasite that caused the patient or carer to seek treatment.

Reduced susceptibility of the causal agent to a drug. WHO defines resistance to antimalarials as the ability of a parasite strain to survive and/or multiply despite the administration and absorption of a medicine given in doses equal to – or higher than – those usually recommended but within the tolerance of the subject, with the caveat that the form of the drug active against the parasite must be able to gain access to the parasite or the infected red blood cell for the duration of the time necessary for its normal action. Resistance to antimalarials arises because of the selection of parasites with genetic mutations or gene amplifications that confer reduced susceptibility.

Sexual stages of malaria parasites present in the host red blood cells, which are infective to the anopheline mosquito.

Persistent liver stages of *P. vivax* and *P. ovale* malaria that remain dormant in host hepatocytes for a fixed interval (3–45 weeks) before maturing to hepatic schizonts. These then burst and release merozoites, which infect red blood cells. Hypnozoites are the source of relapses.

A dark brown granular pigment formed by malaria parasites as a by-product of haemoglobin catabolism. The pigment is evident in mature trophozoites and schizonts.

Parasites released into the host bloodstream when a hepatic or erythrocytic schizont bursts. These then invade the red blood cells.

Antimalarial treatment with a single medicine (either a single active compound or a synergistic combination of two compounds with related mechanism of action).

**Plasmodium.** A genus of protozoan vertebrate blood parasites that includes the causal agents of malaria. *Plasmodium falciparum*, *P. malariae*, *P. ovale* and *P. vivax* cause malaria in humans.

The life-cycle of the malaria parasite when it first enters the host. Following inoculation into a human by the female anopheline mosquito, sporozoites invade parenchyma cells in the host liver and multiply within the hepatocytes for 5–12 days, forming hepatic schizonts. These then burst liberating merozoites into the bloodstream, which subsequently invade red blood cells.

In *P. vivax* and *P. ovale* infections only, this comprises cure as defined above plus prevention of relapses.

An antigen-based stick, cassette or card test for malaria in which a coloured line indicates that plasmodial antigens have been detected.

The recurrence of asexual parasitaemia after treatment of the infection with the same infection that caused the original illness (in endemic areas now defined by molecular genotyping). This results from incomplete clearance of parasitaemia by treatment and is therefore different to a relapse in *P. vivax* and *P. ovale* infections.

The recurrence of asexual parasitaemia following treatment. This can be caused by a recrudescence, a relapse (in *P. vivax* and *P. ovale* infections only) or a new infection.

The recurrence of asexual parasitaemia in *P. vivax* and *P. ovale* malaria deriving from persisting liver stages. Relapse occurs when the blood stage infection has been eliminated but hypnozoites persist in the liver and mature to form hepatic schizonts. After a variable interval of weeks (tropical strains) or months (temperate strains) the hepatic schizonts burst and liberate merozoites into the bloodstream.

Young usually ring-shaped intra-erythrocytic malaria parasites, before malaria pigment is evident under microscopy.

Mature malaria parasites in host liver cells (hepatic schizonts) or red blood cells (erythrocytic schizonts) that are undergoing nuclear division. This process is called schizogony.

Resistance to antimalarials emerges and spreads because of the selective survival advantage that resistant parasites have in the presence of antimalarials that they are resistant to. Selection pressure describes the intensity and magnitude of the selection process; the greater the proportion of parasites in a given parasite population exposed to concentrations of an antimalarial that allow proliferation of resistant, but not sensitive parasites, the greater is the selection pressure.

Haemoglobin concentration of  $<5$  g/100 ml.

Acute falciparum malaria with signs of severity and/or evidence of vital organ dysfunction.

Motile malaria parasites that are infective to humans, inoculated by a feeding female anopheline mosquito. The sporozoites invade hepatocytes.

The intensity of malaria transmission measured by the frequency with which people living in an area are bitten by anopheline mosquitoes carrying sporozoites. This is often expressed as the annual entomological inoculation rate (EIR), which is the number of inoculations of malaria parasites received by one person in one year.

Stage of development of the malaria parasites within host red blood cells from the ring stage and before nuclear division. Mature trophozoites contain visible malaria pigment.

. Symptomatic infection with malaria parasitaemia without signs of severity and/or evidence of vital organ dysfunction.

## ABBREVIATIONS

ACT	artemisinin-based combination therapy
AL	artemether-lumefantrine combination
AQ	amodiaquine
AS	artesunate
AS+AQ	artesunate + amodiaquine combination
AS+MQ	artesunate + mefloquine combination
AS+SP	artesunate + sulfadoxine-pyrimethamine combination
CI	confidence interval
CQ	chloroquine
EIR	entomological inoculation rate
HIV/AIDS	human immunodeficiency virus/ acquired immunodeficiency syndrome
HRP2	histidine-rich protein 2
IC <sub>50</sub>	concentration providing 50% inhibition
MIC	minimum inhibitory concentration
MQ	mefloquine
OR	odds ratio
PCR	polymerase chain reaction
pLDH	<i>parasite</i> -lactate dehydrogenase
RCT	randomized controlled trial
RDT	rapid diagnostic test
RR	relative risk
SP	sulfadoxine–pyrimethamine
WHO	World Health Organization
WMD	weighted mean difference